NICE-40NCT04981899
PET-Adapted Low-Dose Nivolumab With NICE-40 for Relapsed/Refractory Classical Hodgkin Lymphoma
StatusCompleted
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Phase 1/2 → Phase 2 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 14 words
- Trial completed
- Final enrollment: 37 participants (planned 30)
- Study sites: 3 to 5
- Secondary endpoints: 5 to 6
- Study title shortened, about 17 words
- Minor Site details revised at 1 of 3 sitesv4
Notable Primary completion date changed from estimate of Oct 1, 2023 to May 1, 2026v3 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Oct 1, 2024 to Sep 15, 2026
- Secondary endpoints: 3 to 5
- Site details revised at 3 of 3 sites
- Notable Primary completion date: Mar 1, 2023 to Oct 1, 2023
- Study completion date: Mar 1, 2023 to Oct 1, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall Response Rate (ORR)
Timeframe: 12 months
Secondary (6)
Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03
Duration of Response (DOR)
Overall Survival (OS)
Progression-Free Survival (PFS)
Progression-Free Survival Rate (Post Autologous Transplant)
Show 1 moreShow less
Overall Survival (Post Autologous Transplant)
Arms and interventions
Main armExperimental
Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT. Patients with \<CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment.
Drugs: Nivolumab, Ifosfamide, Carboplatin, Etoposide
Sites
5 sites in 1 country